- Home
- FWONK vs NTRA Comparison
FWONK vs NTRA Comparison
Compare FWONK & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWONK
- NTRA
- Stock Information
- Founded
- FWONK 1950
- NTRA 2003
- Country
- FWONK United States
- NTRA United States
- Employees
- FWONK N/A
- NTRA N/A
- Industry
- FWONK Broadcasting
- NTRA Medical Specialities
- Sector
- FWONK Industrials
- NTRA Health Care
- Exchange
- FWONK Nasdaq
- NTRA Nasdaq
- Market Cap
- FWONK 24.9B
- NTRA 21.7B
- IPO Year
- FWONK N/A
- NTRA 2015
- Fundamental
- Price
- FWONK $98.93
- NTRA $172.16
- Analyst Decision
- FWONK Buy
- NTRA Strong Buy
- Analyst Count
- FWONK 9
- NTRA 16
- Target Price
- FWONK $109.67
- NTRA $193.50
- AVG Volume (30 Days)
- FWONK 932.3K
- NTRA 971.6K
- Earning Date
- FWONK 11-06-2025
- NTRA 11-11-2025
- Dividend Yield
- FWONK N/A
- NTRA N/A
- EPS Growth
- FWONK N/A
- NTRA N/A
- EPS
- FWONK 1.07
- NTRA N/A
- Revenue
- FWONK $3,866,000,000.00
- NTRA $1,964,250,000.00
- Revenue This Year
- FWONK $20.50
- NTRA $23.93
- Revenue Next Year
- FWONK $11.45
- NTRA $15.60
- P/E Ratio
- FWONK $93.05
- NTRA N/A
- Revenue Growth
- FWONK 4.71
- NTRA 44.38
- 52 Week Low
- FWONK $74.34
- NTRA $117.27
- 52 Week High
- FWONK $106.26
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- FWONK 45.49
- NTRA 59.37
- Support Level
- FWONK $97.85
- NTRA $164.83
- Resistance Level
- FWONK $102.45
- NTRA $176.82
- Average True Range (ATR)
- FWONK 2.28
- NTRA 5.06
- MACD
- FWONK -0.13
- NTRA -0.04
- Stochastic Oscillator
- FWONK 23.35
- NTRA 68.21
About FWONK Liberty Media Corporation Series C Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.